Laura Momoko Asakura, PharmD, BCOP, BCSPS, discusses the equitable use of oncology treatment pathway tools, highlighting that their utilization remains consistent across patient groups regardless of race, ethnicity, or insurance status.
Laura Momoko Asakura, PharmD, BCOP, BCSPS
Advertisement
Articles by Laura Momoko Asakura, PharmD, BCOP, BCSPS
Advertisement
Latest Updated Articles
ASCO 2025: Oncology Pathway Tools Show Consistent Usage Across Patient GroupsPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First At-Home Treatment Device for Depression
2
Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer
3
Integrated Specialty Pharmacy Services Improve Speed to Therapy and Clinical Outcomes
4
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
5
